Program Information
Therapeutic Benefit in Spatially Fractionated Radiotherapy (GRID) Using Helical Tomotherapy
G Narayanasamy1*, X Zhang1 , A Meigooni2,3 , X Liang1,4 , N Paudel1 , S Morrill1 , S Maraboyina1 , L Peacock1 , J Penagaricano1 , (1) Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, (2) Comprehensive Cancer Center of Nevada, Las Vegas, NV, (3) Department of Radiation Oncology, University of Nevada Las Vegas, NV, (4) University of Florida Health Proton Therapy Institute, Jacksonville, FL
Presentations
TU-H-BRC-7 (Tuesday, August 2, 2016) 4:30 PM - 6:00 PM Room: Ballroom C
Purpose:
The aim of this project is to study the therapeutic ratio (TR) for helical Tomotherapy (HT) based spatially fractionated radiotherapy (GRID). Estimation of TR was based on the linear-quadratic cell survival model by comparing the normal cell survival in a HT GRID to that of a uniform dose delivery in an open-field for the same tumor survival.
Methods:
HT GRID plan was generated using a patient specific virtual GRID block pattern of non-divergent, cylinder shaped holes using MLCs. TR was defined as the ratio of normal tissue surviving fraction (SF) under HT GRID irradiation to an open field irradiation with an equivalent dose that result in the same tumor cell SF. The ratio was estimated from DVH data on ten patient plans with deep seated, bulky tumor approved by the treating radiation oncologist. Dependence of the TR values on radio-sensitivity of the tumor cells and prescription dose were also analyzed.
Results:
The mean ± standard deviation (SD) of TR was 4.0±0.7 (range: 3.1 to 5.5) for the 10 patients with single fraction dose of 20 Gy and tumor cell SF of 0.5 at 2 Gy. In addition, mean±SD of TR = 1±0.1 and 18.0±5.1 were found for tumor with SF of 0.3 and 0.7, respectively. Reducing the prescription dose to 15 and 10 Gy lowered the TR to 2.0±0.2 and 1.2±0.04 for a tumor cell SF of 0.5 at 2 Gy. In this study, the SF of normal cells was assumed to be 0.5 at 2 Gy.
Conclusion:
HT GRID displayed a significant therapeutic advantage over uniform dose from an open field irradiation. TR increases with the radioresistance of the tumor cells and with prescription dose.
Contact Email: